Back Home About Us

CROI 2015: Tenofovir Alafenamide as Effective but Safer for Kidneys and Bones than TDF

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil fumarate (TDF), according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle. A second study showed that TAF has less detrimental effects on the kidneys and bones compared with TDF. TAF has been submitted for approval in the U.S. and Europe.

alt

Read more:

CROI 2015: Putting On Too Much Weight After Starting ART Increases Chronic Inflammation

A return to normal weight after starting antiretroviral therapy (ART) can be beneficial for very sick, underweight individuals living with HIV -- but further weight gain appears to increase markers of inflammation associated with metabolic complications and poorer survival, according to a study reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: Week-on, Weekend-Off HIV Treatment Controls Viral Load in Young People

Taking an efavirenz-based antiretroviral regimen during the week and taking no medication on 2 days over the weekend was just as effective as daily treatment at controlling viral load in an 11-country trial of adolescents and young people, Karina Butler from Our Lady’s Children’s Hospital in Dublin reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

alt

Read more:

CROI 2015: The Quest for a Cure for HIV [VIDEO]

Research towards a cure for HIV continues, despite some recent setbacks. Several investigators presented their work in a session on HIV persistence, latency reversal, and viremia rebound at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) this week in Seattle. There is still enthusiasm in the HIV cure field, said John Mellors of the University of Pittsburgh, but progress will be slow.

alt

Read more:

CROI 2015: Weekends Off Treatment Works Well for Some Young People with HIV [VIDEO]

Taking breaks from antiretroviral therapy on the weekend did not lead to viral rebound or other problems for adolescents and young adults who had prolonged viral suppression on efavirenz-based regimens, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: HIV Care in New York City [VIDEO]

Timely linkage to HIV care increased to 76% and achievement of viral suppression within a year of starting antiretroviral treatment rose to almost 70% over the past several years in New York City, but there are still notable disparities across population subgroups and more remains to be done, according to a study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: PrEP Use Rising in San Francisco, but Scale-Up Could Cut New Infections

Use of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, better known as PrEP, is increasing in San Francisco, but it is still only reaching about one-third of people who could benefit, and wider use could reduce new HIV infections by 70%, according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: HIV Maturation Inhibitor BMS-955176 Looks Promising In Early Study

A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

alt

Read more:

CROI 2015: PrEP Stops 86% of HIV Infections in PROUD Study

A study of pre-exposure prophylaxis (PrEP), the English PROUD study, demonstrated the highest effectiveness yet seen for this method of HIV prevention, the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle heard today. The effectiveness was 86%; for every 20 infections that might have occurred in participants, 17 were stopped by PrEP. 

alt

Read more: